Seasonal Covid-19 vaccination update

14 March 2024

This spring, the NHS will offer a COVID-19 vaccine to people at high risk of serious disease and who are therefore most likely to benefit from vaccination. Last year, data showed that people who received a booster in the autumn programme were around 53% less likely to be admitted to hospital with Covid-19 later. 

Throughout the pandemic, the most significant risk factor has been age. The clinical risk for severe disease is higher for people over 75 years old. You may also have higher risk of severe disease if you are immunosuppressed as a result of your medication, or if you have additional health concerns.

Some of the medications that are listed as causing immunosuppression are used in MS. They include Lemtrada (alemtuzumab), Kesimpta (ofatumumab), rituximab, and steroids such as prednisolone if taken for longer than a month. 

If you are not sure whether you are included in a clinical risk group, check with your GP or MS team. 

These are the groups who will be offered a COVID-19 booster vaccine this spring:

  • residents in a care home for older adults
  • all adults aged 75 years and over
  • all people aged 6 months or over who are immunosuppressed, as laid out in the UK HSA Green Book 

The NHS is aiming to complete this vaccination programme from 15 April through to 30 June 2024. 

Find out more

Covid-19 Immunisation Green Book: Written by the UK Health Security Agency as a handbook for health professionals to support the response to Covid-19.

JCVI statement on COVID-19 vaccination in spring 2024 and considerations on future vaccination: Advice from the government on the current plans for future vaccinations.

Coronavirus, Covid-19 and multiple sclerosis: Our main information page on the pandemic.

Covid-19 vaccines and boosters for people with MS: Our update on Covid-19 vaccines and boosters.